Botulinum toxin for the lower urinary tract

BJU International

Volumn 105, Issue 8, 2010, Pages 1046-1058

  Chuang, Yao Chi ^c   Kuo, Hann Chorng ^a   Chancellor, Michael B ^b  

^a TZU CHI UNIVERSITY   (Taiwan)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BCG VACCINE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CYCLOOXYGENASE 2; LIPOSOME; NERVE GROWTH FACTOR; NEUROTRANSMITTER; PLACEBO; RECEPTOR PROTEIN; SNARE PROTEIN;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AUTONOMIC DYSFUNCTION; BLADDER SPHINCTER; CLINICAL TRIAL; CYSTITIS; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DYSURIA; EJACULATION DISORDER; HEMATURIA; HUMAN; IMPAIRED BLADDER EMPTYING; LOWER URINARY TRACT SYMPTOM; MICTURITION DISORDER; NEUROTRANSMISSION; NONHUMAN; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN SYNTHESIS INHIBITION; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE RETENTION; WEAKNESS;

ADMINISTRATION, INTRAVESICAL; BOTULINUM TOXINS; HUMANS; INJECTIONS, INTRALESIONAL; LOWER URINARY TRACT SYMPTOMS; MALE; NEUROMUSCULAR AGENTS; PROSTATIC DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; URINARY BLADDER DISEASES;

EID: 77950271289     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09317.x     Document Type: Review

References (84)

1. Smith CP, Chancellor MB. Emerging role of botulinum toxin in the treatment of voiding dysfunction. J Urol 2004 171 : 2128 2137
2. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001 8 (Suppl. 5 21 9
3. Aoki KR. A comparison of the safety margins of Botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 2001 39 : 1815 1820
4. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988 139 : 919 922
5. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000 164 : 692 697
6. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003 62 : 259 264
7. Kozaki S, Miki A, Kamata Y, Ogasawara J, Sakaguchi G. Immunological characterization of papain-induced fragments of Clostridium botulinum type A neurotoxin and interaction of the fragments with brain synaptosomes. Infect Immun 1989 57 : 2634 2639
8. Dong M, Yeh F, Tepp WH et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006 312 : 592 596
9. Modugno N, Priori A, Berardelli A, Vacca L, Mercuri B, Manfredi M. Botulinum toxin restores presynaptic inhibition of group Ia afferents in patients with essential tremor. Muscle Nerve 1998 21 : 1701 1705
10. Smith CP, Boone TB, de Groat WC, Chancellor MB, Somogyi GT. Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull 2003 61 : 165 171
11. Thesleff S, Molgo J, Tågerud S. Trophic interrelations at the neuromuscular junction as revealed by the use of botulinal neurotoxins. J Physiol (Paris) 1990 84 : 167 173
12. de Paiva A, Meunier FA, Molgó J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999 96 : 3200 3205
13. Haferkamp A, Schurch B, Reitz A et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol 2004 46 : 784 791
14. Compérat E, Reitz A, Delcourt A, Capron F, Denys P, Chartier-Kastler E. Histologic features in the urinary bladder wall affected from neurogenic overactivity - a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 2006 50 : 1058 1064
15. Apostolidis A, Jacques TS, Freeman A et al. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 2008 53 : 1245 1253
16. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005 26 : 785 793
17. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin type A reduces formalin-induced pain. Pain 2004 107 : 125 133
18. Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB. Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 2004 172 : 1529 1532
19. Khera M, Somogyi GT, Kiss S, Boone TB, Smith CP. Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 2004 45 : 987 993
20. Smith CP, Gangitano DA, Munoz A et al. Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Neurochem Intl 2008 52 : 1068 1075
21. 3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of Botulinum toxin for human detrusor overactivity. J Urol 2005 174 : 977 982
22. Giannantoni A, Di Stasi SM, Nardicchi V et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 2006 175 : 2341 2344
23. Chuang YC, Yoshimura N, Huang CC, Chiang PH, Wu M, Chancellor MB. Intraprostatic capsaicin injection as a novel model for non-bacteria prostatitis. Eur Urol 2007 51 : 1119 1127
24. Chuang YC, Yoshimura N, Huang CC, Chiang PH, Wu M, Chancellor MB. Intraprostatic botulinum toxin A injection inhibits COX-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat. J Urol 2008 180 : 742 748
25. Chuang YC, Yoshimura N, Huang CC, Chiang PH, Wu M, Chancellor MB. Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide induced cystitis in rats. Eur Urol 2009 56 : 159 166
26. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007 177 : 2231 2236
27. Schurch B, de Seze M, Denys P et al. Botox Detrusor Hyperreflexia Study Team. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled6-month study. J Urol 2005 174 : 196 200
28. Giannantoni A, Mearini E, Del Zingaro M. Six-year follow-up of BoNT-A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol 2009 55 : 705 711
29. Chancellor MB. Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery. Int Urol Nephrol 2009 Epub ahead of print, DOI 101.1007/s11255-009-9600-7
30. Kessler TM, Danuser H, Schumacher M, Studer VE, Burkhard FC. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 2005 24 : 231 236
31. Rajkumar GN, Small DR, Mustafa AW, Conn G. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 2005 96 : 848 852
32. Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005 174 : 984 989
33. Schulte-Baukloh H, Weiss C, Stolze T, Sturzebecher B, Knispel HH. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology 2005 66 : 82 7
34. Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004 63 : 868 872
35. Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin in patients with non-neurogenic detrusor overactivity refractory to anticholinergics. Urology 2005 66 : 94 8
36. Werner M, Schmid DM, Schussler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 2005 192 : 1735 1740
37. Schmid DM, Sauermann P, Werner M et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006 176 : 177 185
38. Kuo HC. Will suburothelial injection of a small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology 2006 68 : 993 997
39. Ghei M, Maraj BH, Miller R et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 2005 174 : 1873 1877
40. Brubaker L, Richter HE, Visco A et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008 180 : 217 222
41. Dmochowski R, Chapple C, Nitti V et al. Efficacy and safety of botulinum toxin A (onabotulinumtoxinA) in idiopathic overactive bladder: a double-blind, placebo-controlled, randomized, dose-ranging trial (presented at the 2009 Western Section of the AUA meeting). J Urol 2010 (in press)
42. Mehnert U, Boy S, Schmid M et al. A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging. World J Urol 2009 27 : 397 403
43. Kuo HC, Chen YC, Chen CY, Chancellor MB. Trans-abdominal ultrasound measurement of detrusor wall thickness in patients with overactive bladder. Tzu Chi Med J 2009 21 : 129 135
44. Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin A for idiopathic detrusor overactivity. J Urol 2007 178 : 1359 1363
45. Zermann DH, Ishigooka M, Schubert J et al. Trigonum and bladder base injection of botulinum toxin A (BTX) in patients with severe urgency-frequency-syndrome refractory to conservative medical treatment and electrical stimulation. Neurourol Urodyn 2001 20 : 412 413
46. Karsenty G, Elzayat E, Delapparent T, St-Denis B, Liemileux MC, Corcus J. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol 2007 177 : 1011 1014
47. Mascarenhas F, Cocuzza M, Gomes CM, Leão N. Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients. Neurourol Urodyn 2008 27 : 311 314
48. Kalsi V, Apostolidis A, Gonzales G, Elneil S, Dasgupta P, Fowler CJ. Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity. Eur Urol 2008 54 : 181 187
49. Sahai A, Sangster P, Kalsi V, Khan MS, Fowler CJ, Dasgupta P. Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable. BJU Int 2009 103 : 630 634
50. White WM, Pickens RB, Doggweiller R, Klein FA. Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population. J Urol 2008 180 : 2522 2526
51. Schurch B, Denys P, Kozma CM et al. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol 2007 52 : 850 858
52. Schulte-Baukloh H, Schobert J, Stolze T et al. Efficacy of botulinum-A bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn 2006 25 : 110 115
53. Reitz A, Stohrer M, Kramer G et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004 45 : 510 515
54. Smith CP, Radziszewski P, Borkowski A et al. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology 2004 64 : 871 875
55. Kuo HC. Preliminary results of suburothelial injection of botulinum A toxin in the treatment of chronic interstitial cystitis. Urol Int 2005 75 : 170 174
56. Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol 2006 49 : 704 709
57. Giannantoni A, Porena M, Costantini E et al. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J Urol 2008 179 : 1031 1034
58. Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int 2009 104 : 657 661
59. Liu HT, Kuo HC. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology 2007 70 : 463 468
60. Chuang CC, Kim DK, Chiang PH, Chancellor MB. Bladder botulinum toxin A injection can benefit patients with radiation and chemical cystitis. BJU Int 2008 012 : 704 706
61. Kuo HC. Effect of botulinum A toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology 2003 61 : 550 554
62. Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 1990 71 : 24 6
63. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum A toxin as a treatment of detrusor sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 1996 155 : 1023 1029
64. Maria G, Destito A, Lacquaniti S et al. Relief by botulinum toxin of voiding dysfunction due to prostatitis. Lancet 1998 352 : 625
65. Phelan MW, Franks M, Somogyi GT et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 2001 165 : 1107 1110
66. Lim SK, Quek PL. Intraprostatic and bladder-neck injection of botulinum A toxin in treatment of males with bladder-neck dyssynergia: a pilot study. Eur Urol 2008 53 : 620 625
67. Kuo HC. Effectiveness of treatment of voiding dysfunction after radical hysterectomy by botulinum A toxin urethral injection. Urol Int 2005 75 : 247 251
68. Chen JL, Chen CY, Kuo HC. Botulinum toxin A injection to the bladder neck and urethra for medically refractory lower urinary tract symptoms in men without prostatic obstruction. J Formos Med Assoc 2009 108 : 950 956
69. Kuo HC. Recovery of detrusor function after urethral botulinum A toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction. Urology 2007 69 : 57 61
70. Pennefather JN, Lau WAK, Mitchelson F, Ventura S. The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies. J Auton Pharmacol 2000 20 : 193 206
71. Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA. Botox induced prostatic involution. Prostate 1998 37 : 44
72. Chuang YC, Chancellor MB. The application of Botulinum toxin in the prostate. J Urol 2006 176 : 2376 2386
73. Chuang YC, Huang CC, Kang HY et al. Novel action of Botulinum toxin on the stromal and epithelial components of prostate gland. J Urol 2006 173 : 1158 1163
74. Lin ATL, Yang AH, Chen KK. Effect of Botulinum toxin A on the contractile function of dog prostate. Eur Urol 2007 52 : 582 589
75. Kuo HC. Prostate botulinum toxin A injection- an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005 65 : 670 674
76. Chuang YC, Chiang PH, Huang CC et al. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 2005 66 : 775 779
77. Chuang YC, Chiang PH, Yoshimura N et al. Sustained beneficial effects of intraprostatic botulinum toxin type A injection on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 2006 98 : 1033 1037
78. Park DS, Cho TW, Lee YK et al. Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia. Yonsei Med J 2006 31 : 706 714
79. Silva J, Silva C, Saraiva L et al. Intraprostatic botulinum toxin type A injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement: effect on prostate Volume and micturition resumption. Eur Urol 2008 53 : 153 159
80. Silva J, Pinto R, Carvalho T et al. Intraprostatic botulinum toxin type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment. BMC Urol 2009 9 : 9
81. Brisinda G, Cadeddu F, Vanella S, Mazzeo P, Marniga G, Maria G. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology 2009 73 : 90 4
82. Petrou SP, Parker AS, Crook JE et al. Botulinum a toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: a phase1/2 study. Mayo Clin Proc 2009 84 : 702 706
83. Caccin P, Rossetto O, Rigoni M, Johnson E, Schiavo G, Montecucco C. VAMP/synaptobrevin cleavage by tetanus and botulinum neurotoxins is strongly enhanced by acidic liposomes. FEBS Lett 2003 542 : 132 136
84. Chuang YC, Tyagi P, Huang CC et al. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol 2009 182 : 786 792